Loading…
← CockpitCompetitor Analysis › 1609.HK Star Sports Medicine Co., Ltd Class HOpen in the cockpit ↗

Star Sports Medicine Co., Ltd Class H1609.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum laggard 4
Mkt cap
$364M
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$1.07M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+49.7 pp
WACC 5.9%
Hurdle
-50 pp
Req g minus delivered
Close · HKDHK$53.45
1D+1.8%
1W-1.8%
1M-10.4%
3M-62.3%
6M-72.8%
YTDn/a
1Yn/a
ATR %11.0%
52w lowhigh82.1% off high

What Star Sports Medicine does

Employees: 384

Star Sports Medicine at a glance

Size Star Sports Medicine (1609.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $364M, the 836th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$53.45 on 18 Nov 2026.

Performance Over six months the shares fell 72.8%, against -14.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 23.1% over the last twelve months (peer median +7.1%); the operating margin is 37.2% (peer median 9.4%).

Valuation It trades at 3.7× enterprise value to sales against a peer median of 1.8× (10th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +37%, so the hurdle is -50 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 49.7 points above its cost of capital (5.9% WACC).

Relative performance

25507510021 May 202621 Aug 202618 Nov 2026Peer median 851609.HK 28
Six months, rebased to 100: Star Sports Medicine against the median of its 20 peers (local-currency closes).

Star Sports Medicine financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aHK$437MHK$355MHK$264MHK$170M
Revenue growth—+23%+35%+55%—
Gross profitn/aHK$320MHK$241MHK$191MHK$118M
EBITDAn/aHK$179MHK$126MHK$76.6MHK$48.4M
Net incomen/aHK$149MHK$103MHK$63.1MHK$46.9M
Free cash flown/aHK$135MHK$73.0MHK$64.8MHK$56.8M
Capital expendituren/aHK$37.1MHK$29.4MHK$23.5MHK$9.90M
Total debtn/aHK$36.3MHK$24.0MHK$9.17MHK$12.4M

Quarterly statements and history in the cockpit →

Star Sports Medicine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%SBSCV688338BWAY3005626748VBSN605186041830EMBCYDES458870CLTN6882731609.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Star Sports Medicine is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×100×200×SBSCV688338BWAY3005626748VBSN2041605186041830YDES4736CERS4588706882731609.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Star Sports Medicine is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%SBS688338300562VBSNEMBC4588706882731609.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Star Sports Medicine is the large dot.

Star Sports Medicine competitors and peer comparison

How Star Sports Medicine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Star Sports Medicine against its 20 peers (data as of 18 Nov 2026)
Measure1609.HKPeer medianRank in peer set
1-month return-10.4%-12.0%10th highest of 21
6-month return-72.8%-14.4%lowest of 20
Distance from 52-week high-82.1%-43.6%lowest of 21
Revenue growth (TTM)+23.1%+7.1%4th highest of 21
Operating margin37.2%9.4%highest of 21
EV / Sales3.7×1.8×10th most expensive of 21
Growth the price implies (Req g, 7 yrs)-13.1%-2.3%3rd least demanding of 15
Growth delivered (Del g)+36.8%+3.9%2nd highest of 15
Hurdle (Req g minus delivered)-50.0 pp-0.3 pp2nd least demanding of 15
ROIC minus cost of capital+49.7 pp+7.0 pphighest of 19
EV / EBITDA8.9×10.2×7th cheapest of 13
Net debt / EBITDA-7.1×-1.2×2nd least indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%3.7×-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%1.8×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%24.8×n/an/a
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%4.2×5.7%+3.4%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%4.8×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%1.8×-4.2%-6.0%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%5.4×18.4%+4.4%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%218.3×n/an/a
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%1.1×-12.7%-1.3%
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%1.5×17.1%+18.1%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%7.8×n/an/a
InBody 041830.KSSouth Korea$380M-13%+22%22%1.4×-10.3%+16.9%
Embecta EMBCUnited States$345M+99%-8%26%1.6×-19.9%-0.1%
YD Bio YDESUnited States$344M+7%+17%-883%571.2×n/an/a
Taidoc Technology 4736.TWTaiwan$387M0%0%19%1.8×-9.5%-6.6%
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%1.7×n/an/a
Cerus CERSUnited States$392M-28%+14%-12%1.8×n/an/a
SEERS 458870.KSSouth Korea$392M-70%+174%37%5.5×-6.3%+247.0%
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%1.4×-0.3%-0.7%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%4.2×35.3%+5.2%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%1.0×-17.6%+15.4%

Questions

Which companies are Star Sports Medicine's closest peers?
The cockpit's peer set: Stratec (SBS.DE), CapsoVision (CV), Beijing Succeeder Technology (688338.SS), Brainsway Ltd Sponsored ADR (BWAY), Guangdong Transtek Medical Electronics (300562.SZ), Yantai Zhenghai Bio-Tech (300653.SZ), ACRO Biomedical (6748.TWO), IVF HARTMANN (VBSN.SW).
Is Star Sports Medicine expensive compared with its peers?
On ev / sales it trades at 3.7× against a peer median of 1.8×, 10th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +37%, so the hurdle is -50 pp: the price already allows for a slowdown.
How has Star Sports Medicine stock performed?
Over six months to 18 Nov 2026 the shares returned -72.8% against -14.4% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.